The Primary Biliary Cholangitis market report covers emerging drugs, current treatment practices, Primary Biliary Cholangitis market share of the individual therapies, current and forecasted Primary Biliary Cholangitis Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Primary Biliary Cholangitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Primary Biliary Cholangitis Market Key Facts
According to the National Organization for Rare Disorders (NORD), it has been estimated that PBC is one of the most common autoimmune diseases, affecting nearly 1 in 1000 women over the age of 40.
According to “Orphanet”, Affected individuals are usually in their fifth to seventh decades of life at the time of diagnosis, and 90% are women. Annual incidence is estimated at between 1/1,430,000 and 1/20,400 inhabitants and prevalence at between 1/150,000 and 1/1,063 inhabitants (depending on age and sex).
As per the study conducted by Teru Kumagi et al., titled “Primary biliary cirrhosis”, Primary biliary cirrhosis prevalence is estimated to be between 6.7 and 940 cases per million‐population (the latter in women >40 yrs old in United Kingdom), while its incidence is estimated to be between 0.7 and 49 cases per million‐population per year.
Visit For Sample Pages:
https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market
Key Benefits of Primary Biliary Cholangitis Market Report
Primary Biliary Cholangitis market report provides an in-depth analysis of Primary Biliary Cholangitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Primary Biliary Cholangitis market report will help in developing business strategies by understanding the Primary Biliary Cholangitis Market trends & developments, key players and future market competition that will shape and drive the Primary Biliary Cholangitis market in the upcoming years.
The Primary Biliary Cholangitis market report covers Primary Biliary Cholangitis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Primary Biliary Cholangitis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Primary Biliary Cholangitis Market
The Primary Biliary Cholangitis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Primary Biliary Cholangitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Primary Biliary Cholangitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Primary Biliary Cholangitis Epidemiology
The Primary Biliary Cholangitis epidemiology section covers insights about historical and current Primary Biliary Cholangitis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Primary Biliary Cholangitis Drugs Uptake and Key Market Players
Primary Biliary Cholangitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Biliary Cholangitis market or expected to get launched in the market during the study period. The analysis covers Primary Biliary Cholangitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Some of the emerging therapies in Primary Biliary Cholangitis market include EDP‐305, Elafibranor, TQA3526, CR845, and others.
Key companies in Primary Biliary Cholangitis market include Enanta Pharmaceuticals, Genfit, Chia Tai Tianqing Pharmaceutical, Cara Therapeutics and others.
Table of Content
1. Key Insights
2. Executive Summary
3. Primary Biliary Cholangitis Competitive Intelligence Analysis
4. Primary Biliary Cholangitis Market Overview at a Glance
5. Primary Biliary Cholangitis Disease Background and Overview
6. Primary Biliary Cholangitis Patient Journey
7. Primary Biliary Cholangitis Epidemiology and Patient Population
8. Primary Biliary Cholangitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cholangitis Unmet Needs
10. Key Endpoints of Primary Biliary Cholangitis Treatment
11. Primary Biliary Cholangitis Marketed Products
12. Primary Biliary Cholangitis Emerging Therapies
13. Primary Biliary Cholangitis Seven Major Market Analysis
14. Attribute Analysis
15. Primary Biliary Cholangitis Market Outlook (7 major markets)
16. Primary Biliary Cholangitis Access and Reimbursement Overview
17. KOL Views on the Primary Biliary Cholangitis Market.
18. Primary Biliary Cholangitis Market Drivers
19. Primary Biliary Cholangitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
